Literature DB >> 22955261

Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.

Donna L White1, Shahriar Tavakoli-Tabasi, Jill Kuzniarek, David J Ramsey, Hashem B El-Serag.   

Abstract

BACKGROUND: African Americans have lower reported likelihood of hepatitis C virus-related cirrhosis than whites. It is unknown whether relative differences in the distribution of adipose tissue, lean mass, and other anthropometric measurements may explain these observed interethnic differences in disease risk. AIM: : To evaluate the association between anthropometric measurements and advanced liver disease in a cross-sectional study of African American and white male veterans.
METHODS: We used the validated FibroSURE-ActiTest to assess hepatic pathology, and direct segmental multichannel bioelectric impedance analysis for anthropometric measurements. Race-stratified logistic regression was employed to evaluate risk of high fibrosis progression rate (FPR) and advanced inflammation (A2 to A3).
RESULTS: Among 330 eligible males (59% African American), there were 43 white and 57 African American males with high FPR, and 70 African American and 59 white with advanced inflammation. Percentage body fat (%BF) was a stronger predictor of high FPR risk than was a high body mass index in African Americans [odds ratio (OR)(adj)=2.08; 95% confidence interval (CI),0.83-5.23 for highest %BF vs. lowest tertile and OR(adj)=1.50; 95% CI,0.60-3.75 for obese vs. normal body mass index, respectively], but not in whites. Highest lean leg mass was associated with a nonsignificant increased risk of both high FPR and advanced inflammation in African Americans (OR(highFPRadj)=1.73; 95% CI, 0.73-4.10; OR(AdvancedinflammationAdj)=1.65; 95% CI, 0.76-3.56) versus a decreased risk of both in whites (OR(highFPRadj)=0.62; 95% CI, 0.21-1.79; OR(AdvancedinflammationAdj)=0.58; 95% CI, 0.22-1.48).
CONCLUSIONS: Interethnic differences in nontraditional anthropometric measurements like %BF suggests their potential role in understanding interethnic differences in hepatitis C virus-related liver disease risk in males.

Entities:  

Mesh:

Year:  2012        PMID: 22955261      PMCID: PMC3437036          DOI: 10.1097/MCG.0b013e318266f6eb

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  49 in total

1.  Accuracy of eight-polar bioelectrical impedance analysis for the assessment of total and appendicular body composition in peritoneal dialysis patients.

Authors:  G Medici; C Mussi; A L Fantuzzi; M Malavolti; A Albertazzi; G Bedogni
Journal:  Eur J Clin Nutr       Date:  2005-08       Impact factor: 4.016

2.  Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans.

Authors:  Ke-Qin Hu; Sue L Currie; Hui Shen; Ramsey C Cheung; Samuel B Ho; Edmund J Bini; John D McCracken; Tim Morgan; Norbert Bräu; Warren N Schmidt; Lennox Jeffers; Teresa L Wright
Journal:  Dig Dis Sci       Date:  2007-01-17       Impact factor: 3.199

3.  Epidemiology of hepatitis C among veterans with alcoholic liver disease. The VA Cooperative Study Group 275.

Authors:  C L Mendenhall; T Moritz; S Rouster; G Roselle; A Polito; S Quan; R K DiNelle
Journal:  Am J Gastroenterol       Date:  1993-07       Impact factor: 10.864

4.  An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.

Authors:  K Patel; Y Benhamou; E M Yoshida; K D Kaita; S Zeuzem; M Torbenson; E Pulkstenis; G M Subramanian; J G McHutchison
Journal:  J Viral Hepat       Date:  2008-10-24       Impact factor: 3.728

5.  Bioelectrical impedance analysis for the evaluation of hepatic fibrosis in patients with chronic hepatitis C infection.

Authors:  Fadi Antaki; M Margaret French; Dilip K Moonka; Stuart C Gordon
Journal:  Dig Dis Sci       Date:  2007-11-13       Impact factor: 3.199

6.  Demographics of a large cohort of urban chronic hepatitis C patients.

Authors:  Firdous A Siddiqui; Murray N Ehrinpreis; James Janisse; Ravi Dhar; Elizabeth May; Milton G Mutchnick
Journal:  Hepatol Int       Date:  2008-07-25       Impact factor: 6.047

7.  Ethnic differences in hepatic steatosis: an insulin resistance paradox?

Authors:  Richard Guerrero; Gloria L Vega; Scott M Grundy; Jeffrey D Browning
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

8.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

9.  Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: non-Markov multistate model analysis.

Authors:  Peter Bacchetti; Ross Boylan; Jacquie Astemborski; Hui Shen; Shruti H Mehta; David L Thomas; Norah A Terrault; Alexander Monto
Journal:  PLoS One       Date:  2011-05-27       Impact factor: 3.240

10.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962

View more
  1 in total

1.  Sex hormone pathway gene polymorphisms are associated with risk of advanced hepatitis C-related liver disease in males.

Authors:  Donna L White; Yanhong Liu; Jose Garcia; Hashem B El-Serag; Li Jiao; Spiridon Tsavachidis; Luis M Franco; Ju-Seog Lee; Shahriar Tavakoli-Tabasi; David Moore; Radoslav Goldman; Jill Kuzniarek; David J Ramsey; Fasiha Kanwal; Marco Marcelli
Journal:  Int J Mol Epidemiol Genet       Date:  2014-10-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.